How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "9171"
  ["article_id"]=>
  string(4) "9171"
  [1]=>
  string(105) "Probiotic Bulgarian yogurt ‘feasible’ to achieve good health and well-being on Mars missions"
  ["article_title"]=>
  string(105) "Probiotic Bulgarian yogurt ‘feasible’ to achieve good health and well-being on Mars missions"
  [2]=>
  string(156) "Freshly made Bulgarian yogurt can feasibly be incorporated into an astronaut's diet to boost gut health and overall wellness in support of humanityâs"
  ["short_description"]=>
  string(156) "Freshly made Bulgarian yogurt can feasibly be incorporated into an astronaut's diet to boost gut health and overall wellness in support of humanityâs"
  [3]=>
  string(202) "Freshly made Bulgarian yogurt can feasibly be incorporated into an astronaut's diet to boost gut health and overall wellness in support of humanityâs extraterrestrial ambitions, says a new study."
  ["description"]=>
  string(202) "Freshly made Bulgarian yogurt can feasibly be incorporated into an astronaut's diet to boost gut health and overall wellness in support of humanityâs extraterrestrial ambitions, says a new study."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(163) "https://www.nutraingredients.com/Article/2024/01/23/Fresh-probiotic-Bulgarian-yogurt-feasible-for-Mars-missions?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(163) "https://www.nutraingredients.com/Article/2024/01/23/Fresh-probiotic-Bulgarian-yogurt-feasible-for-Mars-missions?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-23 17:23:00"
  ["add_date"]=>
  string(19) "2024-01-23 17:23:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:37"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Probiotic Bulgarian yogurt ‘feasible’ to achieve good health and well-being o

Freshly made Bulgarian yogurt can feasibly be incorporated into an astronaut's diet to boost gut health and overall 

array(40) {
  [0]=>
  string(4) "9135"
  ["article_id"]=>
  string(4) "9135"
  [1]=>
  string(122) "HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq"
  ["article_title"]=>
  string(122) "HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq"
  [2]=>
  string(122) "HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq"
  ["short_description"]=>
  string(122) "HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq"
  [3]=>
  string(186) "
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq
"
  ["description"]=>
  string(186) "
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(186) "https://www.globenewswire.com/news-release/2024/01/23/2813810/0/en/HEPHAISTOS-Pharma-secures-a-2-million-seed-round-with-xista-science-ventures-Foundation-Fournier-Majoie-and-Noshaq.html"
  ["blog_url"]=>
  string(186) "https://www.globenewswire.com/news-release/2024/01/23/2813810/0/en/HEPHAISTOS-Pharma-secures-a-2-million-seed-round-with-xista-science-ventures-Foundation-Fournier-Majoie-and-Noshaq.html"
  [15]=>
  string(19) "2024-01-23 17:20:00"
  ["add_date"]=>
  string(19) "2024-01-23 17:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:28"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Found

HEPHAISTOS-Pharma secures a €2 million seed round with xista sc

array(40) {
  [0]=>
  string(4) "9136"
  ["article_id"]=>
  string(4) "9136"
  [1]=>
  string(135) "HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq"
  ["article_title"]=>
  string(135) "HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq"
  [2]=>
  string(135) "HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq"
  ["short_description"]=>
  string(135) "HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq"
  [3]=>
  string(199) "
HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq
"
  ["description"]=>
  string(199) "
HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ventures, la Fondation Fournier-Majoie et Noshaq
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(201) "https://www.globenewswire.com/news-release/2024/01/23/2813810/0/fr/HEPHAISTOS-Pharma-s%C3%A9curise-un-tour-de-table-de-2-millions-avec-xista-science-ventures-la-Fondation-Fournier-Majoie-et-Noshaq.html"
  ["blog_url"]=>
  string(201) "https://www.globenewswire.com/news-release/2024/01/23/2813810/0/fr/HEPHAISTOS-Pharma-s%C3%A9curise-un-tour-de-table-de-2-millions-avec-xista-science-ventures-la-Fondation-Fournier-Majoie-et-Noshaq.html"
  [15]=>
  string(19) "2024-01-23 17:20:00"
  ["add_date"]=>
  string(19) "2024-01-23 17:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:28"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

HEPHAISTOS-Pharma sécurise un tour de table de €2 millions avec xista science ven

HEPHAISTOS-Pharma sécurise un tour de table de €2 millions a

array(40) {
  [0]=>
  string(4) "9137"
  ["article_id"]=>
  string(4) "9137"
  [1]=>
  string(108) "German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN"
  ["article_title"]=>
  string(108) "German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN"
  [2]=>
  string(108) "German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN"
  ["short_description"]=>
  string(108) "German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN"
  [3]=>
  string(108) "German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN"
  ["description"]=>
  string(108) "German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(178) "https://www.globenewswire.com/news-release/2024/01/23/2813771/0/en/German-Pain-Association-DGS-and-Pharmaceutical-Company-Avextra-Join-Forces-to-Launch-Their-New-Study-OCEAN.html"
  ["blog_url"]=>
  string(178) "https://www.globenewswire.com/news-release/2024/01/23/2813771/0/en/German-Pain-Association-DGS-and-Pharmaceutical-Company-Avextra-Join-Forces-to-Launch-Their-New-Study-OCEAN.html"
  [15]=>
  string(19) "2024-01-23 16:30:00"
  ["add_date"]=>
  string(19) "2024-01-23 16:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:28"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch The

German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN

array(40) {
  [0]=>
  string(4) "9217"
  ["article_id"]=>
  string(4) "9217"
  [1]=>
  string(67) "2024 Health IT trends in India: Expanded healthcare AI applications"
  ["article_title"]=>
  string(67) "2024 Health IT trends in India: Expanded healthcare AI applications"
  [2]=>
  string(150) "Aside from clinical decision and diagnosis support, AI technology is also anticipated to assist with personalised treatments, clinical trials, and sel"
  ["short_description"]=>
  string(150) "Aside from clinical decision and diagnosis support, AI technology is also anticipated to assist with personalised treatments, clinical trials, and sel"
  [3]=>
  string(210) "Aside from clinical decision and diagnosis support, AI technology is also anticipated to assist with personalised treatments, clinical trials, and self health management, says Augnito founder Rustom Lawyer.&#nl"
  ["description"]=>
  string(210) "Aside from clinical decision and diagnosis support, AI technology is also anticipated to assist with personalised treatments, clinical trials, and self health management, says Augnito founder Rustom Lawyer.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(106) "https://www.healthcareitnews.com/news/asia/2024-health-it-trends-india-expanded-healthcare-ai-applications"
  ["blog_url"]=>
  string(106) "https://www.healthcareitnews.com/news/asia/2024-health-it-trends-india-expanded-healthcare-ai-applications"
  [15]=>
  string(19) "2024-01-23 15:15:46"
  ["add_date"]=>
  string(19) "2024-01-23 15:15:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

2024 Health IT trends in India: Expanded healthcare AI applications

Aside from clinical decision and diagnosis support, AI technology is also anticipated to assist with personalised treatm

array(40) {
  [0]=>
  string(4) "9138"
  ["article_id"]=>
  string(4) "9138"
  [1]=>
  string(26) "Ex dividend NOK 0.75 today"
  ["article_title"]=>
  string(26) "Ex dividend NOK 0.75 today"
  [2]=>
  string(100) "The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024."
  ["short_description"]=>
  string(100) "The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024."
  [3]=>
  string(107) "
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.
"
  ["description"]=>
  string(107) "
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(98) "https://www.globenewswire.com/news-release/2024/01/23/2813708/0/en/Ex-dividend-NOK-0-75-today.html"
  ["blog_url"]=>
  string(98) "https://www.globenewswire.com/news-release/2024/01/23/2813708/0/en/Ex-dividend-NOK-0-75-today.html"
  [15]=>
  string(19) "2024-01-23 15:00:00"
  ["add_date"]=>
  string(19) "2024-01-23 15:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:28"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Ex dividend NOK 0.75 today

The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.75 as from today, 23.01.2024.

array(40) {
  [0]=>
  string(4) "9139"
  ["article_id"]=>
  string(4) "9139"
  [1]=>
  string(116) "Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion"
  ["article_title"]=>
  string(116) "Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion"
  [2]=>
  string(171) "ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS23 JANUARY 2024 at 9.00 EET         Change in Orion Group Ex"
  ["short_description"]=>
  string(171) "ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS23 JANUARY 2024 at 9.00 EET         Change in Orion Group Ex"
  [3]=>
  string(801) "
ORION CORPORATION 
STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS

23 JANUARY 2024 at 9.00 EET 
        
Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion

René Lindell has been appointed Chief Financial Officer of Orion Group as of 1 May 2024. He will start already as of 1 April 2024 as Executive Advisor (until 30 April 2024) and member of the Group Executive Management Board and will report to President and CEO Liisa Hurme. Lindell currently holds the position of Chief Financial Officer at Rovio Entertainment Corporation. He holds a Master of Science in Economics and a Ph.D. in Engineering.
"
  ["description"]=>
  string(801) "
ORION CORPORATION 
STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS

23 JANUARY 2024 at 9.00 EET 
        
Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion

René Lindell has been appointed Chief Financial Officer of Orion Group as of 1 May 2024. He will start already as of 1 April 2024 as Executive Advisor (until 30 April 2024) and member of the Group Executive Management Board and will report to President and CEO Liisa Hurme. Lindell currently holds the position of Chief Financial Officer at Rovio Entertainment Corporation. He holds a Master of Science in Economics and a Ph.D. in Engineering.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(181) "https://www.globenewswire.com/news-release/2024/01/23/2813715/0/en/Change-in-Orion-Group-Executive-Management-Board-Ren%C3%A9-Lindell-appointed-Chief-Financial-Officer-of-Orion.html"
  ["blog_url"]=>
  string(181) "https://www.globenewswire.com/news-release/2024/01/23/2813715/0/en/Change-in-Orion-Group-Executive-Management-Board-Ren%C3%A9-Lindell-appointed-Chief-Financial-Officer-of-Orion.html"
  [15]=>
  string(19) "2024-01-23 15:00:00"
  ["add_date"]=>
  string(19) "2024-01-23 15:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:28"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Change in Orion Group Executive Management Board – René Lindell appointed Chief

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS

23 JANUARY 2024 at

array(40) {
  [0]=>
  string(4) "9140"
  ["article_id"]=>
  string(4) "9140"
  [1]=>
  string(144) "Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline"
  ["article_title"]=>
  string(144) "Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline"
  [2]=>
  string(5) "  "
  ["short_description"]=>
  string(5) "  "
  [3]=>
  string(12) "
  
"
  ["description"]=>
  string(12) "
  
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(212) "https://www.globenewswire.com/news-release/2024/01/23/2813696/0/en/Press-Release-Sanofi-to-acquire-Inhibrx-Inc-adding-potential-best-in-class-rare-disease-asset-for-Alpha-1-Antitrypsin-Deficiency-to-pipeline.html"
  ["blog_url"]=>
  string(212) "https://www.globenewswire.com/news-release/2024/01/23/2813696/0/en/Press-Release-Sanofi-to-acquire-Inhibrx-Inc-adding-potential-best-in-class-rare-disease-asset-for-Alpha-1-Antitrypsin-Deficiency-to-pipeline.html"
  [15]=>
  string(19) "2024-01-23 14:30:00"
  ["add_date"]=>
  string(19) "2024-01-23 14:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare diseas

 

array(40) {
  [0]=>
  string(4) "9141"
  ["article_id"]=>
  string(4) "9141"
  [1]=>
  string(242) "Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique"
  ["article_title"]=>
  string(242) "Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutique"
  [2]=>
  string(5) "  "
  ["short_description"]=>
  string(5) "  "
  [3]=>
  string(12) "
  
"
  ["description"]=>
  string(12) "
  
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(272) "https://www.globenewswire.com/news-release/2024/01/23/2813696/0/fr/Communiqu%C3%A9-de-presse-Sanofi-va-acqu%C3%A9rir-Inhibrx-Inc-et-ajouter-%C3%A0-son-portefeuille-Maladies-rares-un-actif-pour-le-traitement-du-d%C3%A9ficit-en-alpha-1-antitrypsine-potentiellement-le-m.html"
  ["blog_url"]=>
  string(272) "https://www.globenewswire.com/news-release/2024/01/23/2813696/0/fr/Communiqu%C3%A9-de-presse-Sanofi-va-acqu%C3%A9rir-Inhibrx-Inc-et-ajouter-%C3%A0-son-portefeuille-Maladies-rares-un-actif-pour-le-traitement-du-d%C3%A9ficit-en-alpha-1-antitrypsine-potentiellement-le-m.html"
  [15]=>
  string(19) "2024-01-23 14:30:00"
  ["add_date"]=>
  string(19) "2024-01-23 14:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeu

 

array(40) {
  [0]=>
  string(4) "9142"
  ["article_id"]=>
  string(4) "9142"
  [1]=>
  string(148) "Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure"
  ["article_title"]=>
  string(148) "Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure"
  [2]=>
  string(91) "PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET"
  ["short_description"]=>
  string(91) "PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET"
  [3]=>
  string(164) "
PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
23 January 2024, 07:00 am CET
"
  ["description"]=>
  string(164) "
PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
23 January 2024, 07:00 am CET
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(207) "https://www.globenewswire.com/news-release/2024/01/23/2813680/0/en/Sequana-Medical-announces-DSMB-approval-to-start-randomized-MOJAVE-cohort-US-Phase-1-2a-study-of-DSR-2-0-for-treatment-of-heart-failure.html"
  ["blog_url"]=>
  string(207) "https://www.globenewswire.com/news-release/2024/01/23/2813680/0/en/Sequana-Medical-announces-DSMB-approval-to-start-randomized-MOJAVE-cohort-US-Phase-1-2a-study-of-DSR-2-0-for-treatment-of-heart-failure.html"
  [15]=>
  string(19) "2024-01-23 14:00:00"
  ["add_date"]=>
  string(19) "2024-01-23 14:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phas

PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
23

array(40) {
  [0]=>
  string(4) "9027"
  ["article_id"]=>
  string(4) "9027"
  [1]=>
  string(63) "Older Adults Average 20.7 Total Health Care Contact Days a Year"
  ["article_title"]=>
  string(63) "Older Adults Average 20.7 Total Health Care Contact Days a Year"
  [2]=>
  string(150) "MONDAY, Jan. 22, 2024  -- Older adults have a mean of 20.7 total health care contact days per year, according to a study published online Jan. 23 in t"
  ["short_description"]=>
  string(150) "MONDAY, Jan. 22, 2024  -- Older adults have a mean of 20.7 total health care contact days per year, according to a study published online Jan. 23 in t"
  [3]=>
  string(254) "MONDAY, Jan. 22, 2024  -- Older adults have a mean of 20.7 total health care contact days per year, according to a study published online Jan. 23 in the Annals of Internal Medicine.Ishani Ganguli, M.D., M.P.H., from Brigham and Women's Hospital in..."
  ["description"]=>
  string(254) "MONDAY, Jan. 22, 2024  -- Older adults have a mean of 20.7 total health care contact days per year, according to a study published online Jan. 23 in the Annals of Internal Medicine.Ishani Ganguli, M.D., M.P.H., from Brigham and Women's Hospital in..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(100) "https://www.drugs.com/news/older-adults-average-20-7-total-health-care-contact-days-year-117208.html"
  ["blog_url"]=>
  string(100) "https://www.drugs.com/news/older-adults-average-20-7-total-health-care-contact-days-year-117208.html"
  [15]=>
  string(19) "2024-01-23 06:13:48"
  ["add_date"]=>
  string(19) "2024-01-23 06:13:48"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Older Adults Average 20.7 Total Health Care Contact Days a Year

MONDAY, Jan. 22, 2024 -- Older adults have a mean of 20.7 total health care contact days per year, according to a study

array(40) {
  [0]=>
  string(4) "9028"
  ["article_id"]=>
  string(4) "9028"
  [1]=>
  string(61) "Gene Therapy for Sickle Cell Disease Likely Cost-Effective at"
  ["article_title"]=>
  string(61) "Gene Therapy for Sickle Cell Disease Likely Cost-Effective at"
  [2]=>
  string(150) "MONDAY, Jan. 22, 2024  -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published o"
  ["short_description"]=>
  string(150) "MONDAY, Jan. 22, 2024  -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published o"
  [3]=>
  string(250) "MONDAY, Jan. 22, 2024  -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published online Jan. 23 in the Annals of Internal Medicine.Anirban Basu, Ph.D., from The Comparative Health..."
  ["description"]=>
  string(250) "MONDAY, Jan. 22, 2024  -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published online Jan. 23 in the Annals of Internal Medicine.Anirban Basu, Ph.D., from The Comparative Health..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(85) "https://www.drugs.com/news/gene-therapy-sickle-cell-likely-cost-effective-117211.html"
  ["blog_url"]=>
  string(85) "https://www.drugs.com/news/gene-therapy-sickle-cell-likely-cost-effective-117211.html"
  [15]=>
  string(19) "2024-01-23 06:02:44"
  ["add_date"]=>
  string(19) "2024-01-23 06:02:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Gene Therapy for Sickle Cell Disease Likely Cost-Effective at

MONDAY, Jan. 22, 2024 -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, ac